Cargando…

Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response

AIM: To analyze locally advanced rectal cancer (LARC) patients and tumor characteristics during the period of total neoadjuvant therapy (TNT) and explore the risk factors that may predict poor tumor regression in response to TNT. MATERIALS AND METHODS: The data of 120 LARC patients who received TNT...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Haoyu, Cao, Ke, Li, Ganbin, Zhai, Zhiwei, Wei, Guanghui, Qu, Hao, Wang, Zhenjun, Han, Jiagang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685996/
https://www.ncbi.nlm.nih.gov/pubmed/36439518
http://dx.doi.org/10.3389/fonc.2022.1049228
_version_ 1784835642022166528
author Zhang, Haoyu
Cao, Ke
Li, Ganbin
Zhai, Zhiwei
Wei, Guanghui
Qu, Hao
Wang, Zhenjun
Han, Jiagang
author_facet Zhang, Haoyu
Cao, Ke
Li, Ganbin
Zhai, Zhiwei
Wei, Guanghui
Qu, Hao
Wang, Zhenjun
Han, Jiagang
author_sort Zhang, Haoyu
collection PubMed
description AIM: To analyze locally advanced rectal cancer (LARC) patients and tumor characteristics during the period of total neoadjuvant therapy (TNT) and explore the risk factors that may predict poor tumor regression in response to TNT. MATERIALS AND METHODS: The data of 120 LARC patients who received TNT from December 2016 and September 2019 in our hospital were retrospectively analyzed. The clinicopathological characteristics of patients with different tumor regression responses were compared. Then we divided patients into two groups according to the carcinoembryonic antigen (CEA) clearance pattern after chemoradiation to explore risk factors that might predict the tumor regression response. RESULTS: Of 120 LARC patients, 34 (28.3%) exhibited poor regression. Stratified analysis by tumor response showed that patients with poor response to TNT were more likely to obtain elevated CEA during the course of TNT (all P < 0.05). For those with elevated pretreatment CEA, fewer patients with poor response obtained normal CEA after chemoradiation (13.6% vs. 72.7%, P < 0.001). Besides, less patients’ CEA levels in the poor response group decreased by greater than 50% after chemoradiation when compared with that in the good response group (18.2% vs. 60.6%, P = 0.002). Stratified analysis by CEA clearance pattern after chemoradiation showed patients who obtained an elevated pretreatment CEA and decreased by less than 50% after chemoradiation were more likely to have poor response to TNT compared to others (76.2% vs. 18.2%, P < 0.001). Logistic multivariate analysis revealed that cN2 (95% CI 1.553-16.448), larger tumors (95% CI 2.250-21.428) and CEA clearance pattern after chemoradiation (95% CI 1.062-66.992) were independent risk factors for poor tumor regression response. CONCLUSION: Approximately one-fourth of LARC patients with TNT achieved a poor regression response. Here, cN2, larger tumor size before treatment and elevated CEA levels were considered predictive features of a poor response. Active surveillance of CEA levels during the TNT course are potentially important, and CEA levels after chemoradiation might have important implications for the tumor response to TNT.
format Online
Article
Text
id pubmed-9685996
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96859962022-11-25 Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response Zhang, Haoyu Cao, Ke Li, Ganbin Zhai, Zhiwei Wei, Guanghui Qu, Hao Wang, Zhenjun Han, Jiagang Front Oncol Oncology AIM: To analyze locally advanced rectal cancer (LARC) patients and tumor characteristics during the period of total neoadjuvant therapy (TNT) and explore the risk factors that may predict poor tumor regression in response to TNT. MATERIALS AND METHODS: The data of 120 LARC patients who received TNT from December 2016 and September 2019 in our hospital were retrospectively analyzed. The clinicopathological characteristics of patients with different tumor regression responses were compared. Then we divided patients into two groups according to the carcinoembryonic antigen (CEA) clearance pattern after chemoradiation to explore risk factors that might predict the tumor regression response. RESULTS: Of 120 LARC patients, 34 (28.3%) exhibited poor regression. Stratified analysis by tumor response showed that patients with poor response to TNT were more likely to obtain elevated CEA during the course of TNT (all P < 0.05). For those with elevated pretreatment CEA, fewer patients with poor response obtained normal CEA after chemoradiation (13.6% vs. 72.7%, P < 0.001). Besides, less patients’ CEA levels in the poor response group decreased by greater than 50% after chemoradiation when compared with that in the good response group (18.2% vs. 60.6%, P = 0.002). Stratified analysis by CEA clearance pattern after chemoradiation showed patients who obtained an elevated pretreatment CEA and decreased by less than 50% after chemoradiation were more likely to have poor response to TNT compared to others (76.2% vs. 18.2%, P < 0.001). Logistic multivariate analysis revealed that cN2 (95% CI 1.553-16.448), larger tumors (95% CI 2.250-21.428) and CEA clearance pattern after chemoradiation (95% CI 1.062-66.992) were independent risk factors for poor tumor regression response. CONCLUSION: Approximately one-fourth of LARC patients with TNT achieved a poor regression response. Here, cN2, larger tumor size before treatment and elevated CEA levels were considered predictive features of a poor response. Active surveillance of CEA levels during the TNT course are potentially important, and CEA levels after chemoradiation might have important implications for the tumor response to TNT. Frontiers Media S.A. 2022-11-10 /pmc/articles/PMC9685996/ /pubmed/36439518 http://dx.doi.org/10.3389/fonc.2022.1049228 Text en Copyright © 2022 Zhang, Cao, Li, Zhai, Wei, Qu, Wang and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhang, Haoyu
Cao, Ke
Li, Ganbin
Zhai, Zhiwei
Wei, Guanghui
Qu, Hao
Wang, Zhenjun
Han, Jiagang
Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response
title Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response
title_full Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response
title_fullStr Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response
title_full_unstemmed Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response
title_short Active surveillance in long period of total neoadjuvant therapy in rectal cancer: Early prediction of poor regression response
title_sort active surveillance in long period of total neoadjuvant therapy in rectal cancer: early prediction of poor regression response
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9685996/
https://www.ncbi.nlm.nih.gov/pubmed/36439518
http://dx.doi.org/10.3389/fonc.2022.1049228
work_keys_str_mv AT zhanghaoyu activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT caoke activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT liganbin activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT zhaizhiwei activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT weiguanghui activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT quhao activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT wangzhenjun activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse
AT hanjiagang activesurveillanceinlongperiodoftotalneoadjuvanttherapyinrectalcancerearlypredictionofpoorregressionresponse